GRI Bio (GRI) Competitors

Ernexa Therapeutics (NASDAQ:ERNA) and GRI Bio (NASDAQ:GRI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

Which has stronger valuation and earnings, ERNA or GRI?

GRI Bio has lower revenue, but higher earnings than Ernexa Therapeutics. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ernexa Therapeutics	$580K	20.96	-$44.54M	-$8.31	-0.19
GRI Bio	N/A	N/A	-$8.21M	-$11.56	-0.12

Which has more risk & volatility, ERNA or GRI?

Ernexa Therapeutics has a beta of 5.42, meaning that its stock price is 442% more volatile than the S&P 500. Comparatively, GRI Bio has a beta of -1.61, meaning that its stock price is 261% less volatile than the S&P 500.

Do institutionals & insiders have more ownership in ERNA or GRI?

70.6% of Ernexa Therapeutics shares are held by institutional investors. Comparatively, 34.0% of GRI Bio shares are held by institutional investors. 1.5% of Ernexa Therapeutics shares are held by company insiders. Comparatively, 0.9% of GRI Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Do analysts rate ERNA or GRI?

GRI Bio has a consensus target price of $22.00, suggesting a potential upside of 1,482.73%. Given GRI Bio's stronger consensus rating and higher possible upside, analysts clearly believe GRI Bio is more favorable than Ernexa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ernexa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
GRI Bio	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media prefer ERNA or GRI?

In the previous week, GRI Bio had 2 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 6 mentions for GRI Bio and 4 mentions for Ernexa Therapeutics. GRI Bio's average media sentiment score of 0.38 beat Ernexa Therapeutics' score of 0.32 indicating that GRI Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ernexa Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
GRI Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is ERNA or GRI more profitable?

GRI Bio has a net margin of 0.00% compared to Ernexa Therapeutics' net margin of -7,652.75%. Ernexa Therapeutics' return on equity of 0.00% beat GRI Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ernexa Therapeutics	-7,652.75%	N/A	-682.08%
GRI Bio	N/A	-337.46%	-197.01%

Summary

GRI Bio beats Ernexa Therapeutics on 9 of the 15 factors compared between the two stocks.